Powerful bactericidal activity of moxifloxacin in human leprosy.
In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P <or= 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.
Pardillo
Fe Eleanor F
FE
Leonard Wood Memorial Center for Leprosy Research, Cebu, Philippines.
Burgos
Jasmin
J
Fajardo
Tranquilino T
TT
Dela Cruz
Eduardo
E
Abalos
Rodolfo M
RM
Paredes
Rose Maria D
RM
Andaya
Cora Evelyn S
CE
Gelber
Robert H
RH
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001372:Aza Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D024841:Fluoroquinolones; D005528:Foot / Q000382:microbiology; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008297:Male; D051379:Mice; D008875:Middle Aged; D000077266:Moxifloxacin; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin